The plasma beta-amyloid 42/40 ratio is a blood-based measure that reflects how much amyloid protein is building up in the brain, and risk tables built around it sort people into categories like “low,” “intermediate,” or “high” probability of having brain amyloid plaques. A lower ratio signals that more of the sticky Aβ42 form is being trapped in the brain rather than circulating freely, which is a hallmark of Alzheimer’s disease pathology. These tables do not diagnose Alzheimer’s on their own, but they help clinicians decide who needs further testing with a PET scan or spinal tap and who can be reassured without those expensive, invasive procedures.
Why a Ratio Instead of a Single Number
Your blood contains two main forms of amyloid-beta: Aβ40 and Aβ42. As Alzheimer’s pathology develops, Aβ42 selectively clumps into plaques in the brain, so less of it makes it back into the bloodstream. Aβ40 does not get trapped in plaques the same way, so its blood levels stay more stable. Measuring the ratio of Aβ42 to Aβ40 captures that selective drop. If you only measured Aβ42 by itself, the result could be thrown off by all sorts of things unrelated to brain amyloid: natural variation in total amyloid production, differences in how blood samples were collected or stored, or even how much protein someone’s body makes overall. The ratio cancels out much of that noise.1Elsevier / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Plasma amyloid β 42/40 ratios as biomarkers for amyloid β cerebral deposition in cognitively normal individuals
This is also why Aβ42 alone turned out to be an unreliable predictor in research. Higher Aβ42 in blood can actually indicate early disease risk, but then levels fall as the disease progresses and more peptide gets locked up in plaques. That rise-then-fall pattern makes a single Aβ42 measurement hard to interpret without knowing where someone is on the disease timeline.2Narra J. Associations between plasma beta amyloid and cognitive decline: A systematic review and meta-analysis The ratio sidesteps this confusion by always moving in one direction as plaques accumulate: downward.
How the Risk Table Is Structured
Rather than drawing one line and declaring everyone above it “negative” and everyone below it “positive,” most risk scoring systems use two cutoffs to create three zones. The logic is straightforward: people near any single cutoff have a real chance of being misclassified if they’re retested, because their values sit in the gray area. By carving out an intermediate zone, the test gains confidence at the extremes. People who score clearly low on the risk scale almost certainly do not have significant brain amyloid; people who score clearly high almost certainly do. The people in the middle need a confirmatory test.
The Amyloid Probability Score, or APS, is one well-studied version of this approach. Developed using data from people with mild cognitive impairment and mild dementia, it converts blood test results into a score from 0 to 100. An APS below 35 places someone in the low-risk group, above 58 in the high-risk group, and between 35 and 58 in the intermediate zone. In the study that validated these cutoffs, the low group had an 88% negative predictive value, meaning 88 out of 100 people classified as low risk truly had a negative amyloid PET scan. The high group had an 83% positive predictive value.3JAMA Network Open. Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment
An expert working group convened by the Global CEO Initiative on Alzheimer’s Disease formally endorsed this two-cutoff model. They noted that roughly 5 to 20 percent of individuals fall in the borderline zone depending on the population, where repeat testing could flip between positive and negative. The intermediate category gives clinicians a way to flag those people for further workup rather than making a premature call.4Nature. Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
How Accurate Is the Ratio on Its Own
Across a combined cohort of 465 participants, the plasma Aβ42/Aβ40 ratio matched amyloid PET results with an area under the curve of 0.84. That is a useful screening test but not quite at the level clinicians want for standalone diagnosis. When researchers added information about whether the person carried the APOE ε4 gene variant, which is the strongest common genetic risk factor for Alzheimer’s, accuracy jumped to an AUC of 0.88 against PET and 0.93 against cerebrospinal fluid amyloid status.5Neurology. Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques This is why most risk tables incorporate APOE status or other variables alongside the raw ratio rather than relying on the ratio alone.
Newer immunoassay platforms have pushed accuracy even higher. One head-to-head comparison of a fully automated immunoassay against the gold-standard mass spectrometry method found the immunoassay’s amyloid risk score achieved an AUC of 0.94 with 92 to 93 percent overall accuracy, and its intermediate zone captured only about 10 to 13 percent of participants.6Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. Comparison of a multi-analyte algorithmic immunoassay blood test with immunoprecipitation mass spectrometry for the detection of amyloid pathology The field is moving fast, and the generation of tests entering clinical practice now outperforms the data from just a few years ago.
What APOE ε4 Status Does to the Numbers
Carrying one or two copies of the APOE ε4 gene variant does more than increase your lifetime risk of Alzheimer’s. It also changes the trajectory of blood biomarkers. Compared to non-carriers, APOE ε4 carriers tend to show a lower Aβ42/Aβ40 ratio at any given age, along with steeper increases over time in other markers like phosphorylated tau and GFAP, a protein associated with brain inflammation.7Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring. Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression This means two people with the same Aβ42/Aβ40 ratio could have meaningfully different risk profiles depending on their genetic background. Risk scoring algorithms account for this by weighting APOE status in the calculation, which is partly why accuracy improves when genotype information is included.
Interestingly, broader genetic risk beyond just APOE also matters. A polygenic risk score for Alzheimer’s (which sums the effects of many common gene variants, excluding the APOE region itself) was associated with greater declines in the Aβ42/Aβ40 ratio specifically among people who do not carry APOE ε4.7Alzheimer’s and Dementia: Diagnosis, Assessment and Disease Monitoring. Plasma biomarker trajectories: Impact of AD genetic risk and clinical progression In plain terms, even if you don’t carry the most famous Alzheimer’s risk gene, your overall genetic makeup still nudges the ratio around. Risk tables that fold in APOE status capture the largest chunk of this genetic influence, though not all of it.
When the Ratio Changes and What That Timeline Looks Like
One of the most striking findings about the Aβ42/Aβ40 ratio is how early it starts to shift. Using two different assay platforms, researchers found that the ratio drops sharply at around 15 Centiloids on an amyloid PET scan, which corresponds to an average age of about 66 years in the study populations. The ratio becomes abnormal roughly two years before a PET scan would officially turn positive, then quickly falls to a stable, low level as preclinical Alzheimer’s disease sets in.8Annals of Neurology. When Does Alzheimer’s Disease Start? Plasma Aβ42/40 Assays Show Steep Changes at Aβ‐PET Centiloid 15, Mean Age of 66 Years
That early drop is a double-edged sword for interpretation. On one hand, it means a blood test could flag someone before a PET scan would. On the other hand, once brain amyloid reaches moderate or high levels, the ratio plateaus. It has already dropped about as far as it is going to go. Longitudinal studies confirm this: the ratio is most informative during the transition from no plaques to early plaque formation, but it has limited ability to track further progression in people who are already amyloid-positive.9Alzheimer’s & Dementia. Longitudinal changes in Alzheimer’s-related plasma biomarkers and brain amyloid For monitoring disease progression over time, clinicians look to other markers like phosphorylated tau or neurofilament light chain, which continue to rise as the disease worsens.
Kidney Function, Obesity, and Other Confounders
A natural concern with any blood test is whether conditions unrelated to the brain could skew the results. Kidney function is the most frequently raised worry, because the kidneys help clear amyloid peptides from the blood. Reduced kidney function does push individual Aβ40 and Aβ42 levels higher in a dose-dependent fashion.10PubMed Central. The association of kidney function with plasma amyloid-β levels and brain amyloid deposition But here is where the ratio pays off: because both peptides are affected roughly equally by impaired kidney clearance, the Aβ42/Aβ40 ratio stays independent of renal function. One study explicitly tested this across multiple measures of kidney impairment and found that while Aβ40 and Aβ42 each climbed with worsening kidney disease, the ratio did not budge.11Wiley Online Library. Plasma Aβ42/Aβ40 ratio is independent of renal function This is a genuine advantage over some other blood biomarkers for Alzheimer’s, like phosphorylated tau and neurofilament light chain, which are more strongly affected by kidney disease.
Body weight is a trickier story. People with obesity have been found to have a ratio about 17.5 percent lower than lean individuals, a gap that could push someone closer to or past a risk cutoff without actually reflecting brain amyloid.12IOS Press. Plasma Amyloid-β Homeostasis Is Associated with Body Mass Index and Weight Loss in People with Overweight and Obesity The mechanism is debated. Some researchers suspect higher blood volume in larger bodies dilutes concentrations, while others have found no significant link between total blood volume and amyloid levels specifically.13Oxford Academic. The association of body mass index and body composition with plasma amyloid beta levels A more recent study suggested that using BMI-specific cutoff thresholds improved amyloid PET prediction, but also flagged a practical headache: rapid weight loss increased variability in blood biomarker levels and led to more misclassifications.14PubMed Central. Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer’s disease If you are significantly overweight or have recently lost a large amount of weight, a clinician interpreting your risk score should factor that in.
Traumatic Brain Injury Can Shift the Ratio for Years
A head injury is another event that alters blood biomarker levels in ways unrelated to Alzheimer’s plaque accumulation. In a large longitudinal study, people who experienced a traumatic brain injury had a lower Aβ42/Aβ40 ratio that persisted for about nine years afterward. Other markers like neurofilament light chain and GFAP remained elevated even longer. The strongest signal was for GFAP, which stayed above normal for nearly 13 years after the injury.15Wiley Online Library. Traumatic brain injury, changes in plasma amyloid, tau, and neurodegenerative biomarkers, and dementia risk For someone with a history of significant head trauma, a low ratio on a blood test might partially reflect the injury itself rather than Alzheimer’s pathology. This does not mean the test is useless in that population, but it adds a layer of interpretive caution that a clinician should weigh when reviewing the risk table result.
Do the Cutoffs Work Equally Well Across Racial Groups
Early Alzheimer’s blood biomarker research was conducted overwhelmingly in white populations, which raised reasonable questions about whether the same cutoffs apply to everyone. Recent studies have started to address this directly. Black individuals have been found to have higher baseline Aβ42/Aβ40 ratios than white individuals, on average, in both cognitively normal and cognitively impaired groups. That difference was consistent regardless of sex, APOE ε4 status, education, body mass index, or whether someone had hypertension or diabetes. The rate of decline over time, however, was the same across racial groups.16Nature Communications. Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals
The higher mean ratio in Black participants is consistent with lower overall prevalence of brain amyloid pathology in many studies, not with the blood test performing differently. When researchers evaluated whether plasma-based screening worked equally well at selecting trial-eligible participants across racial and ethnic groups, they found that eligibility based on plasma was equally effective regardless of group membership, even though the underlying prevalence of amyloid pathology differed.17Wiley Online Library. Racial and ethnic differences in plasma biomarker eligibility for a preclinical Alzheimer’s disease trial So while absolute ratio values differ on average between populations, the test’s ability to sort people correctly appears to hold up. Still, the field recognizes that larger, more diverse validation studies are needed before anyone can be fully confident that a single set of cutoffs works optimally for all groups.
Newer Biomarker Ratios That Build on the Same Idea
The Aβ42/Aβ40 ratio is not the only game in town. Researchers have been combining it with phosphorylated tau measurements, particularly p-tau217 and p-tau181, to create composite ratios that outperform either marker alone. In one head-to-head evaluation, the ratio of p-tau217 to Aβ42 achieved the best overall discrimination of brain amyloid, with an AUC of 0.93.18PMC. Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloid These composite ratios work because they combine two independent signals of Alzheimer’s pathology: amyloid buildup (captured by the drop in Aβ42) and tau phosphorylation (captured by the rise in p-tau). When both signals agree, the test’s confidence goes up.
The p-tau181 ratio with amyloid beta 42 has also shown a specific strength in distinguishing Alzheimer’s from frontotemporal dementia, a different type of neurodegeneration that rarely involves amyloid plaques. Because frontotemporal dementia produces very little amyloid co-pathology, the combination of a tau marker with an amyloid marker cleanly separates the two conditions.19Wiley Online Library. Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer’s disease and non-AD dementias Risk tables are increasingly moving toward these multi-marker panels, where the Aβ42/Aβ40 ratio is one input among several rather than the sole readout.
Sample Handling and Why It Matters for Your Results
Blood biomarkers are sensitive to how samples are collected, transported, and stored, and amyloid peptides are no exception. The good news is that the Aβ42/Aβ40 ratio is more forgiving than the individual peptides. Aβ40 and Aβ42 concentrations remained stable for 24 hours when whole blood was refrigerated, and they declined when stored at room temperature for more than six hours, but because both peptides declined at similar rates, the ratio itself stayed within acceptable range.20PubMed Central. Preanalytical stability of plasma biomarkers for Alzheimer’s disease pathology
Testing against a fully automated immunoassay confirmed this resilience across a range of real-world conditions. Whether whole blood was stored at room temperature for two hours or refrigerated for six, and whether the resulting plasma was subsequently stored at room temperature, refrigerated, or frozen at different temperatures, the Aβ42/Aβ40 ratio recovery remained acceptable.21Nature. The appropriate sample-handling procedure for measuring the plasma β-amyloid level using a fully automated immunoassay Repeated freeze-thaw cycles, which degrade many biological samples, caused less than a six percent decline in individual peptide levels over five cycles and did not reach statistical significance.22Karger Publishers. Stability of Plasma Amyloid-beta 1-40, Amyloid-beta 1-42, and Total Tau Protein over Repeated Freeze/Thaw Cycles This practical robustness is part of what makes blood-based amyloid testing feasible in everyday clinical settings where sample conditions are not always perfectly controlled.
Cost Implications of Using Blood Tests as a First Step
One of the strongest arguments for blood-based amyloid screening is economic. An amyloid PET scan costs thousands of dollars and requires specialized facilities. Cerebrospinal fluid testing requires a lumbar puncture, often done as an inpatient procedure in some healthcare systems. Using a blood biomarker as a triage step, where only people with positive or intermediate results are sent for confirmatory imaging, dramatically reduces the number of expensive tests performed.
A cost-effectiveness analysis found that using blood biomarker triage identified over 98 percent of amyloid-positive patients at a lower average cost per confirmed diagnosis compared to PET scanning everyone. When PET scan access was limited to half the patient pool (a common real-world constraint), blood biomarker triage identified about 91 percent more positive cases than PET alone at a fraction of the per-diagnosis cost.23PubMed Central. Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer’s disease pathology A separate analysis in the Japanese healthcare system estimated cost savings of 40 to 79 percent compared to PET and 6 to 74 percent compared to inpatient cerebrospinal fluid testing, depending on the blood test’s price point and the width of the intermediate zone.24Elsevier. Cost analyses of plasma p-tau217 versus p-tau217/Aβ42 ratio using two-step approach in the Japanese health care system
The intermediate zone has a direct economic impact here. A wider intermediate zone means more people need confirmatory testing, which eats into the savings. A narrower intermediate zone saves more money but risks more misclassifications at the boundary. The tradeoff between these two pressures is a central design choice in any risk scoring system, and different clinical settings may reasonably land on different cutoffs depending on local access to PET scanners and cerebrospinal fluid testing.
What a Risk Table Result Does and Does Not Tell You
A “high probability” result on one of these risk tables means you are likely to have amyloid plaques detectable on a PET scan. It does not mean you have Alzheimer’s dementia or that you will develop it. Plenty of older adults have amyloid plaques and remain cognitively sharp for years. Amyloid is necessary for an Alzheimer’s diagnosis but not sufficient on its own, which is why clinicians combine it with cognitive testing and other biomarkers before reaching any conclusions.
A “low probability” result is more definitive, in a sense: it tells you that significant brain amyloid is unlikely to be present right now. That is valuable information, particularly if someone is experiencing memory concerns, because it shifts the diagnostic workup toward other potential causes like depression, sleep disorders, medication side effects, or a non-Alzheimer’s dementia. The ratio’s high negative predictive value is arguably its greatest clinical strength. Ruling out amyloid pathology quickly and cheaply saves patients from unnecessary anxiety and invasive follow-up procedures while redirecting clinical attention to more likely explanations.
An “intermediate” result is the least satisfying outcome for patients but the most honest one. It means the blood test cannot confidently call the situation one way or the other, and additional testing (typically amyloid PET or cerebrospinal fluid analysis) is warranted. About one in ten people tested will land here, though the exact proportion varies by assay platform and the population being screened. If you receive an intermediate result, it does not mean you are halfway to Alzheimer’s; it means the blood test has reached the limit of what it can tell your clinician, and a more precise measurement is needed.